NBY Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Nanoviricides's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 34.9%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 428.46%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.726, which suggesting that the stock is 27.362% less volatile than S&P 500. In comparison Nanoviricides has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.225%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Nanoviricides's net income of -$2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.07x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Oragenics's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 34.9%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 257.14%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.726, which suggesting that the stock is 27.362% less volatile than S&P 500. In comparison Oragenics has a beta of 0.847, suggesting its less volatile than the S&P 500 by 15.305%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Oragenics's net income of -$2.5M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.07x versus 1.10x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of -2357.27%. NovaBay Pharmaceuticals's return on equity of -461.38% beat Palatin Technologies's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 34.9%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that Palatin Technologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palatin Technologies is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.726, which suggesting that the stock is 27.362% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Palatin Technologies quarterly revenues of $350K. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Palatin Technologies's net income of -$2.4M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.07x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Theriva Biologics's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 34.9%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 419.93%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.726, which suggesting that the stock is 27.362% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. NovaBay Pharmaceuticals's net income of -$1.2M is higher than Theriva Biologics's net income of -$4.4M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.07x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.